Company profile
UK company FC034088, incorporated on 1 January 2017.
Home - IntraBio
IntraBio is a leader in discovering, developing, and commercializing novel therapies and treatments for rare and neurodegenerative diseases with high unmet medical needs.
Company number FC034088
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
Intrabio specializes in developing and discovering novel therapies and treatments aimed at helping those with rare and neurodegenerative diseases with high unmet medical needs.
Successful Phase III trial In this double-blind, placebo-controlled, crossover trial, we randomly assigned patients 4 years of age or older with genetically confirmed Niemann-Pick disease type C in a 1:1 ratio to receive N-acetyl-L-leucine (NALL) for 12 weeks, followed by placebo for 12 weeks, or to receive placebo for 12 weeks, followed by NALL for 12 weeks. NALL met its primary SARA endpoint (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001) and its secondary endpoints. NALL was well-tolerated, with no serious adverse reactions. N Engl J Med 2024; 390:421-431
Successful Phase III trial In this double-blind, placebo-controlled, crossover trial, we randomly assigned patients 4 years of age or older with genetically confirmed Niemann-Pick disease type C in a 1:1 ratio to receive N-acetyl-L-leucine (NALL) for 12 weeks, followed by placebo for 12 weeks, or to receive placebo for 12 weeks, followed by NALL for 12 weeks. NALL met its primary SARA endpoint (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001) and its secondary endpoints. NALL was well-tolerated, with no serious adverse reactions. N Engl J Med 2024; 390:421-431 FDA approved lead compound Aqneursa for NPC on 27 September 2024
